China Pharma Holdings, Inc. (CPHI) analyses
1 analysis in the last 30 days. Latest: .
Market Scanner’s AI analysis of China Pharma Holdings, Inc. (CPHI), updated July 2026: CPHI.US participation in China and Korea events contrasted with overbought technical indicators.
Summary
CPHI.US participation in China and Korea events contrasted with overbought technical indicators.
Recent analyses for CPHI.US noted the company's participation in industry events in China and Korea, alongside broader pharmaceutical sector trends. Technical indicators suggest the asset is in overbought territory with strong buying pressure, though momentum may be shifting. Fundamental data retrieval failed, but available information shows a negative EPS and profit margin, with a recent year-over-year quarterly revenue decline.
Factors discussed — upside
- Participation in CPHI events in China and Korea highlighting innovation and collaboration
- Strong buying pressure indicated by Money Flow Index (MFI)
- Current price above 10-day and 50-day SMAs
Factors discussed — risks
- Relative Strength Index (RSI) in overbought territory (70.94)
- Current price below 200-day SMA
- Negative EPS (-0.54)
- Negative Profit Margin (-88.82%)
- Quarterly Revenue Growth (YoY) of -13.4%
- Industry Events
- Technical Indicators
- Financial Performance
- Market Sentiment
Summary updated .
Analyses
Recent CPHI.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for China Pharma Holdings, Inc.?
- Recent AI analyses of China Pharma Holdings, Inc. discussed upside factors including Participation in CPHI events in China and Korea highlighting innovation and collaboration, strong buying pressure indicated by Money Flow Index (MFI), and current price above 10-day and 50-day SMAs.
- What are the risks for China Pharma Holdings, Inc.?
- Recent AI analyses of China Pharma Holdings, Inc. flagged risks including Relative Strength Index (RSI) in overbought territory (70.94), current price below 200-day SMA, negative EPS (-0.54), negative Profit Margin (-88.82%), and quarterly Revenue Growth (YoY) of -13.4%.
- Is China Pharma Holdings, Inc. bullish or bearish?
- Recent AI analyses of China Pharma Holdings, Inc. examined factors on both sides. Discussed upside: Participation in CPHI events in China and Korea highlighting innovation and collaboration, strong buying pressure indicated by Money Flow Index (MFI), and current price above 10-day and 50-day SMAs. Discussed risks: Relative Strength Index (RSI) in overbought territory (70.94), current price below 200-day SMA, negative EPS (-0.54), negative Profit Margin (-88.82%), and quarterly Revenue Growth (YoY) of -13.4%. These are descriptive observations, not a recommendation.
- What is the latest sentiment on China Pharma Holdings, Inc.?
- Recent analyses for CPHI.US noted the company's participation in industry events in China and Korea, alongside broader pharmaceutical sector trends. Technical indicators suggest the asset is in overbought territory with strong buying pressure, though momentum may be shifting. Fundamental data retrieval failed, but available information shows a negative EPS and profit margin, with a recent year-over-year quarterly revenue decline.
- Bundles used
- gemini-low-v2
Sign in to read every CPHI.US report in the library
Each analysis includes the full reasoning, dissent, and decision rationale from the structured AI pipeline.
Sign in to see full analyses